For decades, men diagnosed with localized prostate cancer have faced a difficult trade-off: aggressive surgery or radiation that often comes with life-altering side effects, or active surveillance that leaves the cancer in place. A new, minimally invasive approach is now challenging that binary choice.

Data published this week in The Journal of Urology from the VAPOR 2 pivotal trial suggests that thermal water vapor ablation—using the Vanquish system—could offer a middle path. In the study of 110 patients, 91 percent of targeted MRI-visible lesions were cleared following a single treatment, all while maintaining low rates of the urinary and erectile dysfunction that often plague traditional interventions.

Why This Data Matters Now

The results from the VAPOR 2 trial represent a significant shift in the focal therapy landscape. Unlike whole-gland treatments that target the entire prostate, focal therapy aims to destroy only the cancerous tissue. The challenge has always been precision; many technologies struggle to reach lesions in anatomically difficult areas of the prostate without damaging surrounding nerves or the urinary sphincter.

The Vanquish system works by delivering sterile water vapor transurethrally. As the vapor condenses, it releases thermal energy that causes cellular necrosis within the targeted zone. Because the energy is confined to natural tissue boundaries, the surrounding structures are largely spared. The study’s findings suggest this mechanism is not only effective but also highly tolerable for patients, with 93 percent reporting satisfaction with the procedure.

The Path to Clinical Adoption

While the results are promising, the medical community is looking closely at the study’s design. The VAPOR 2 trial is a prospective, multicenter, single-arm study involving 235 patients across 26 U.S. sites. The current publication focuses on the initial 110 patients, providing a snapshot of early-stage oncological control and safety.

Dr. Samir Taneja, the study’s co-principal investigator, noted that the ability to minimize impact on surrounding structures provides a vital new option for appropriately selected patients. However, the technology is still moving through the regulatory pipeline. Francis Medical is currently following these patients to the five-year mark to gather the long-term data necessary for a pre-market approval (PMA) submission to the FDA for an expanded indication in prostate cancer management.

Key Takeaways

  • High Clearance Rates: The study reported a 91 percent clearance rate of targeted MRI-visible Grade Group 2 or greater disease after a single treatment.
  • Preservation of Quality of Life: Patients experienced low rates of urinary incontinence and erectile dysfunction, two of the most common complications associated with radical prostatectomy or radiation.
  • Anatomical Versatility: The system demonstrated an ability to treat lesions in challenging locations that have historically limited other focal therapy technologies.

What Experts Say

Medical experts emphasize that while these results are encouraging, they represent a specific cohort of patients with intermediate-risk, localized disease. The long-term durability of water vapor ablation compared to established standards like robotic-assisted surgery remains the primary question for urologists.

As the study continues, the focus will shift from short-term clearance to long-term oncological outcomes. Francis Medical’s next major milestone will be the completion of the five-year follow-up data collection. For the urological community, the next decision point will arrive when that data is submitted to the FDA, which will determine whether this therapy moves from a clinical trial setting into the standard of care for men seeking to avoid the morbidity of traditional prostate cancer treatments.

This article is for informational purposes only. Always consult a qualified healthcare professional before making any medical decisions.